Fat Loss

Also known as: Reta, RC-3R, PEP-3R, GLP-R, GIP/GLP/Glucagon, Triple Agonist

Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials demonstrated unprecedented 24.2% mean body weight reduction at 48 weeks with 12 mg weekly dosing — the largest weight loss ever reported for an anti-obesity drug in a clinical trial. Currently in Phase 3 TRIUMPH trials.

Also known as: NS2330

Triple monoamine reuptake inhibitor for weight management

Also known as: Sema, RC-1S, PEP-1S, GLP-1, GLP-1 Agonist

Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1. FDA-approved as Ozempic (type 2 diabetes, 2017) and Wegovy (chronic weight management, 2021). The STEP trials demonstrated 15–17% mean body weight reduction at 68 weeks with 2.4 mg weekly dosing, establishing it as the leading pharmaceutical treatment for obesity.

Also known as: Tirz, RC-2T, PEP-2T, GIP/GLP, GIP/GLP-1, Dual Agonist

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). The SURMOUNT-1 trial demonstrated 20.9% mean body weight reduction at 72 weeks with 15 mg weekly dosing — surpassing semaglutide in head-to-head efficacy comparisons.

Also known as: SLU PP 332

ERR agonist exercise mimetic

Also known as: 5-amino, NNMT inhibitor

A selective NNMT inhibitor that enhances fat metabolism by increasing cellular NAD+ and energy expenditure.